Advertisement


Rana R. McKay, MD, and Toni K. Choueiri, MD, on RCC: New Findings on Efficacy and Safety of Atezolizumab Plus Cabozantinib

2023 ASCO Annual Meeting

Advertisement

Rana R. McKay, MD, of the University of California, San Diego, and Toni K. Choueiri, MD, of Dana-Farber Cancer Institute and Harvard Medical School, discuss results from the phase III CONTACT-03 study, showing that, for patients with metastatic renal cell carcinoma (RCC), adding the PD-L1 inhibitor atezolizumab to cabozantinib did not improve clinical outcomes compared with treatment with cabozantinib alone. In addition, higher toxicities were observed in the combination arm (Abstract LBA4500).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Rana R McKay: So tell us a little bit about the CONTACT-03 big phase III study that's getting presented at ASCO today. What's the rationale behind why this study was even designed? Toni K Choueiri: I think it's important study, that what we see in practice, that's taking observation from clinic and taking them to a randomized controlled trial. So in clinic we have been seeing a patient being re-challenged with immune checkpoint inhibitor after prior tumor progression on immune checkpoint inhibitor. We've seen it on the genitourinary cancers, we've seen it in kidney cancer, we've seen it in bladder cancer. We hear and there are publications from real world data about other cancers and when you look at the literature, there isn't much randomized studies there, if any. Rana R McKay: So tell me a little bit about the design of CONTACT-03. What is the study? How was it designed? What's the schema? Toni K Choueiri: So the biggest thing was to look if we challenge with immune checkpoint inhibitor has any effect, should we do that? And we use renal cell cancer as a model, self-serving because that's what I treat. And because we could do a study where the study would be A versus A plus B, where the B is the PD-L1 inhibitor, let's say. So in this situation, patients which tumor progressed on prior immune checkpoint inhibitor. And here I don't mean CTLA-4 inhibitor or other, I mean PD-1 or PD-L1 inhibitor. Which we randomized to a TKI cabozantinib at full dose versus cabozantinib plus atezolizumab. Why atezolizumab? PD-L1 inhibitor has single agent activity in metastatic untreated RCC 25%. Plays well with other drugs, so there is a safety data with cabozantinib. And also does not have a major place, or I would say any place, in untreated patient with all the other studies. Rana R McKay: Yeah. Toni K Choueiri: So we conducted that study over 500 patients were randomized. The usual stratification factors here, IMDC risk factor, prior adjuvant, first line, second line. We allowed one prior VEGF inhibitor. Usually that's what the patient receive. And progression-free survival was a primary endpoint. There was really no benefit. Rana R McKay: Yes. Toni K Choueiri: Median progression-free survival was the same in both arm, around over 10 months with cabo single agent or combination, response rate 40%. What we also found, no overall survival, not even a trend. We tried to look at specific subgroups. Our patient who have not received a VEGF TKI, almost 30%, these are probably patients that had nivolumab, ipilimumab. Do they have some benefit compared to the one who were pre-exposed? No. Rana R McKay: Yeah. Toni K Choueiri: We looked at several subgroup, there was nothing there. And also if you look at the toxicity profile, there is no new safety signal. That's great. But overall, at least numerically the toxicities are higher in the combination. Rana R McKay: This is a very relevant study because in clinical practice a lot of people are layering on the TKI post-progression on IO and a lot of times actually you're even compromising the dose of the TKI because you're not able to do full dose of the TKI, whether it be cabozantinib or a different TKI. But this was a really practice changing study. Do you think it's going to actually impact practice come Monday morning? Toni K Choueiri: I think possibly, at least in renal cell cancer. Now I have to say there are two caveat. Could I generalize it first to other solid tumor? Maybe, but the studies should be done. The second thing, this is a PD-L1 inhibitor. In renal cell cancer we know that at least from the frontline data and the adjuvant data that PD-1 inhibitor have been superior. They've shown survival benefit. Let's put it that way, they have work, nivolumab, pembrolizumab, where other PD-L1 inhibitor have worked less. Rana R McKay: Okay. Toni K Choueiri: So could it be due to the PD-L1 inhibitor? Having said so, we have a second study, very similar called TiNivo-2, which our renal cell community has invested in. And that study replaces cabozantinib with tivozanib and uses nivolumab. So that's a PD-1 inhibitor. That study is just finishing accrual and hopefully will get us- Rana R McKay: Yeah. Toni K Choueiri: An answer about PD-1 post-progression prior PD-1/PD-L1. Rana R McKay: Very important study. And I think too, the dosing of the cabozantinib was critical here at 60 milligram standard dosing. Really, cabozantinib has tremendous activity in the modern era and this study showed that. Toni K Choueiri: 40% response rate, whether on independent center review or on investigator assessment. PFS over 10 months. I agree with you. Rana R McKay: Yeah. Toni K Choueiri: That's a bar that is somewhat high. Rana R McKay: Well, thank you so much for this groundbreaking study. I think it's definitely going to inform practice on utilization of IO/post-IO. Thank you, Toni. Toni K Choueiri: Thank you so much.

Related Videos

Solid Tumors

Funda Meric-Bernstam, MD, on HER2-Expressing Solid Tumors: Efficacy and Safety of Trastuzumab Deruxtecan

Funda Meric-Bernstam, MD, of The University of Texas MD Anderson Cancer Center, discusses interim results from the DESTINY-PanTumor02 trial, the first tumor-agnostic global study of fam-trastuzumab deruxtecan-nxki (T-DXd) in a broad range of HER2-expressing solid tumors. This agent showed an encouraging overall response rate, particularly in patients with IHC 3+ expression; durable clinical benefit; and a manageable safety profile in these heavily pretreated patients. T-DXd may be a potential new treatment option for this population (Abstract LBA3000).

Lymphoma
Immunotherapy

Tycel J. Phillips, MD, and Swetha Kambhampati, MD, on Mantle Cell Lymphoma: Real-World Outcomes With Brexucabtagene Autoleucel

Tycel J. Phillips, MD, and Swetha Kambhampati, MD, both of City of Hope National Medical Center, discuss new findings showing that the real-world effectiveness and safety of brexucabtagene autoleucel were similar to data from the pivotal ZUMA-2 trial in patients with relapsed or refractory mantle cell lymphoma, regardless of prior BTK inhibition, bendamustine, or autologous stem cell transplantation (Abstract 7507).

Breast Cancer

Lisa A. Carey, MD, and Javier Cortes, MD, PhD, on HER2-Positive Early Breast Cancer: Chemotherapy De-escalation Under Study in PHERGain Trial

Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Javier Cortes, MD, PhD, of the International Breast Cancer Center and Universidad Europea de Madrid, discuss phase II findings showing that one in three patients with HER2-positive early breast cancer may safely omit chemotherapy. Among the chemotherapy-free patients treated with trastuzumab and pertuzumab, the 3-year invasive disease–free survival was 98.8%, with no distant metastases (Abstract LBA506).

Colorectal Cancer

Sebastian Stintzing, MD, on Colorectal Cancer: Influence of Liquid Biopsy in First-Line Combination Treatment

Sebastian Stintzing, MD, of the Charité Universitätsmedizin Berlin, discusses results from the phase III FIRE-4 study, which showed that liquid biopsy is clinically relevant in verifying mutational status in patients with metastatic colorectal cancer and is efficacious in first-line treatment of FOLFIRI and cetuximab for patients with RAS wild-type disease (Abstract 3507).

Lung Cancer

Narjust Florez, MD, and Roy S. Herbst, MD, on NSCLC: Overall Survival Analysis From the ADAURA Trial of Osimertinib

Narjust Florez, MD, of Dana-Farber Cancer Institute, and Roy S. Herbst, MD, PhD, of Yale Cancer Center, discuss new phase III findings on osimertinib, a third-generation, central nervous system EGFR-TKI, which demonstrated an unprecedented overall survival benefit for patients with EGFR-mutated, stage IB–IIIA non–small cell lung cancer after complete tumor resection, with or without adjuvant chemotherapy (Abstract LBA3).

Advertisement

Advertisement




Advertisement